Entecavir: a potent new antiviral drug for hepatitis B

Bibliography

• WONG DK, CHEUNG AM, O'ROURKE K, NAYLOR CD, DETSKY AS, HEATHCOTE J: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann. Intern. Merl (1993) 119:312–323.
   PubMed Web of Science ®Google Scholar
• LOK AS, MCMAHON BJ: Chronic hepatitis B. Hepatology (2001) 34(6):1225–1241.
   PubMed Web of Science ®Google Scholar
• •Important review with practice guidelines on chronic hepatitis B.
   Google Scholar
• YAMANAKA G, WILSON T, INNAIMO S et al: Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob. Agents Cheinother: (1999) 43(1):190–193.
   PubMed Web of Science ®Google Scholar
• SEIFER M, HAMATAKE RK, COLONNO RJ, STANDRING DN: In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS- 200475 and lobucavir. Antimicrob. Agents Cheinother. (1998) 42(12):3200–3208.
   PubMed Web of Science ®Google Scholar
• INNAIMO SF, SEIFER M, BISACCHI GS, STANDRING DN, ZAHLER R, COLONNO RJ: Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob. Agents Cheinother. (1997) 41(7):1444–1448.
   PubMed Web of Science ®Google Scholar
• COLONNO RJ, GENOVESI EV, MEDINA I et al.: Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection. Infect. Dis. (2001) 184(10):1236–1245.
   Google Scholar
• •Animal study with long-term exposure to entecavir.
   Google Scholar
• GENOVESI EV, LAMB L, MEDINA I et al.: Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Cheinother. (1998) 42(12):3209–3217.
   PubMed Web of Science ®Google Scholar
• MORALEDA G, SAPUTELLI J, ALDRICH CE, AVERETT D, CONDREAY L, MASON WS: Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J. Vim/. (1997) 71(12):9392–9399.
   Web of Science ®Google Scholar
• DANDRI M, BURDA MR, WILL H, PETERSEN J: Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA. Hepatology (2000) 32:139–146.
   PubMed Web of Science ®Google Scholar
• DANDRI M, BURDA MR, BURKLE A et al.: Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation. Hepatology (2002) 35(1):217–223.
   PubMed Web of Science ®Google Scholar
• ZHOU T, SAPUTELLI J, ALDRICH CE,DESLAURIERS M, CONDREAY LD, MASON WS: Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob. Agents Cheinother. (1999) 43(8):1947–1954.
   PubMed Web of Science ®Google Scholar
• MARION PL, SALAZAR FH, WINTERS MA, COLONNO RJ: Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antiinicrob. Agents Cheinothei: (2002) 46(1):82–88.
   PubMed Web of Science ®Google Scholar
• MCKENZIE R, FRIED MW, SALLIE R et al.: Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl. Med. (1995) 333:1099–1105.
   PubMed Web of Science ®Google Scholar
• HONKOOP P, SCHOLTE HR, DE MAN RA, SCHALM SW: Mitochondrial injury. Lessons from the fialuridine trial. Drug Sal: (1997) 17(1):1–7.
   PubMed Web of Science ®Google Scholar
• BRISTOL-MYERS SQUIBB: Data on file (2001).
   Google Scholar
• DE MAN RA, WOLTERS LM, NEVENS F et al.: Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology (2001) 34(3):578–582.
   PubMed Web of Science ®Google Scholar
• HONKOOP P, DE MAN RA, HEIJTINK RA, SCHALM SW: Hepatitis B reactivation after lamivudine. Lancet (1995) 346(8983):1156–1157.
   PubMed Web of Science ®Google Scholar
• HONKOOP P, DE MAN RA, NIESTERS HG, ZONDERVAN PE, SCHALM SW: Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology (2000) 32(3):635–639.
   PubMed Web of Science ®Google Scholar
• WOLTERS LM, HANSEN BE, NIESTERS HG, DEHERTOGH D, DE MAN RA: Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. Hepatol (2002) 37(1):137–144.
   Web of Science ®Google Scholar
• •Viral dynamics during randomised controlled trial with entecavir in humans with calculations on viral decline.
   Google Scholar
• NEVENS F, DE MAN RA, CHUA D et al.: Effectiveness of a low dose of entecavir in treating recurrent viremia in chronic hepatitis B. Hepatology (2000) 32:A869.
   Google Scholar
• LAI CL, ROSMAWATI M, LAO J et al: Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology (2002) 123(6):1831–1838.
   PubMed Web of Science ®Google Scholar
• ••Important randomised controlled trialwith 24 weeks of treatment including entecavir and lamivudine.
   Google Scholar
• HONKOOP P, NIESTERS HG, DE MAN RA, OSTERHAUS AD, SCHALM SW: Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. Hepatol (1997) 26(6):1393–1395.
   PubMed Web of Science ®Google Scholar
• LAI CL: Antiviral therapy for hepatitis B and C in Asians.' Gastroenterol Hepatol (1999) 14(Suppl.):S19–S21.
   Google Scholar
• NIESTERS HG, DE MAN RA, PAS SD, FRIES E, OSTERHAUS AD: Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy. Med. Microbiol (2002) 51(8):695–699.
   PubMed Web of Science ®Google Scholar
• ONO SK, KATO N, SHIRATORI Y et al: The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. Clin. Invest. (2001) 107:449–455.
   Google Scholar
• LEVINE S, HERNANDEZ D, YAMANAKA G et al.: Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In vitro. Andinicrob. Agents Cheinother. (2002) 46(8):2525–2532.
   PubMed Web of Science ®Google Scholar
• •In vitro study on viral mutants in nucleoside analogue therapy.
   Google Scholar
• CHANG TT, HADZIYANNIS S, CIANCIARA J et al.: Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology (2002) 36:A550.
   Google Scholar
• ••Clinical study showing the efficacy of entecavir in patients with lamivudine-resistant HBV mutants.
   Google Scholar
• PERRILLO R, SCHIFF ER, YOSHIDA E et al.: Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology (2000) 32:129–134.
   PubMed Web of Science ®Google Scholar
• SHAKIL A, LILLY L, ANGUS P et al: Entecavir significantly reduces viral load in liver transplant recipients failing lamivudine therapy for HBV. Hepatol (2002) 36:122.
   PubMed Web of Science ®Google Scholar
• •Entecavir study in lamivudine-resistant mutants after liver transplantation.
   Google Scholar